Kromek Group PLC (LON:KMK) CEO Arnab Basu talks to Proactive London's Katie Pilbeam about their revenue and EBITDA expectations for the year ended 30 April 2021 that are in line with market expectations.
Arnab talks through orders and shipments of the company’s medical, nuclear and security screening detection technology which resumed in the final two months of the first half of the year.
This momentum continued throughout the second half as Kromek delivered on previously awarded contracts and won new orders.
His message is, 'we are back on track, as commercial activities really ramp up'.